Blastic plasmacytoid dendritic cell neoplasm in Korean populatio

Not Applicable

Completed

• Conditions: Neoplasms

• Registration Number: KCT0003990
• Lead Sponsor: Samsung Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 September 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Eligibility Criteria
1. Patients = 18 years
2. Pathologically confirmed diagnosis by tissue or bone marrow at each center with
- Blastic plasmacytoid dendritic cell neoplasm
- Blastic NK-cell lymphoma
- Agranular CD4+ natural killer cell leukaemia
- Blastic natural killer leukaemia/lymphoma
- Agranular CD4+CD56+ haematodermic
neoplasm/tumour
3. Antigen expression of CD4 and/or CD56 coupled with at least one plasmacytoid dendritic cell-associated antigen among CD123, TCL1, CD2AP and BDCA2/CD303

Exclusion Criteria

< Exclusion criteria >
1. Acute myeloid leukemia
2. Acute lymphoblastic leukemia
3. Mixed phenotype acute leukemia
4. Any type of B- or T-/NK/T-cell lymphomas
5. Expression of lineage-specific markers for
B cells (CD20, CD79a)
T cells (CD3)
Myeloid cells (myeloperoxidase)
Monocytes (CD11c, CD163, lysozyme).
CD34

Study & Design

• Study Type: Observational Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Disease-free Survival Rate;overall survival rates;Therapeutic response rates

Secondary Outcome Measures

Name	Time	Method
Factors affecting overall survival : age, ECOG, Involving organs, Response to treatment, Treatment, Autologous transplantation/?Allogeneic transplantation